Hansoh Pharmaceutical (03692.HK): NMPA Accepts New Drug Application for Orlotide Injection
NewTimeSpace News: On June 4, 2026, Hansoh Pharmaceutical (03692.HK) issued a voluntary announcement, disclosing that on June 3, 2026, the marketing authorization application for its in-house innovative product Orlotide Injection was accepted by the National Medical Products Administration (NMPA). The indication covers long-term weight management for adult patients with obesity or overweight.
Orlotide is a once-weekly dual agonist targeting GLP‑1 (glucagon‑like peptide‑1) and GIP (glucose‑dependent insulinotropic polypeptide) receptors.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Hansoh Pharmaceutical (03692.HK): Enters Licensing and Equity Investment Transaction with Avere Therapeutics
- InnoTek Establishes Thai Subsidiary and Secures First Liquid Cooling Project to Expand AI Server Infrastructure Business
- Kaifeng Millennium City Park: Top 5A Scenic Area in Henan by Visitor Volume; HK IPO Application Filed
- HANSOH PHARMA(03692.HK): NDA for HS-10568 Injection Accepted by NMPA for Secondary Hyperparathyroidism in Dialysis Patients
